Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004349 · ClinicalTrials.gov registry record
Autoimmune and Autoinflammatory Genetics Study
A clinical trial of Autoimmune Disease and Rheumatic Disease, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 2
- Study locations
NCT06004349: Recruiting study of Autoimmune Disease and Rheumatic Disease, sponsored by NYU Langone Health.
NCT06004349 is a study of Autoimmune Disease and Rheumatic Disease that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 1,500 participants, above the 1,361-participant average among 10 other Autoimmune Disease trials with a reported enrollment target (10% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06004349, a study of Autoimmune Disease and Rheumatic Disease, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.
Conditions Studied
Study Locations (2)
New York
- NYC H+H/Bellevue - New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2032-04-05 |
What NCT06004349 shows while recruiting
NCT06004349 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,361-participant average among 10 other Autoimmune Disease trials with a reported enrollment target (10% higher).
The record links to 4 conditions, with Autoimmune Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06004349 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06004349 about?
NCT06004349 is a clinical study titled "Autoimmune and Autoinflammatory Genetics Study". This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collec...
What is the current status of trial NCT06004349?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-04-15. Estimated completion is 2032-04-05.
What conditions does trial NCT06004349 study?
This clinical trial studies the following conditions: Autoimmune Disease, Rheumatic Disease, Autoinflammatory Disease, VEXAS Syndome.
Who is sponsoring clinical trial NCT06004349?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004349 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06004349's enrollment target sits among peer trials
1,500 2nd of 10 the highest of 10 other Autoimmune Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autoimmune Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Natural History of Bronchiectasis
RECRUITING
-
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI